Guidelines

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

Nicolas Mottet a,*, Joaquim Bellmunt b, c, Michel Bolla d, Erik Briers e, Marcus G. Cumberbatch f, Maria De Santis g, Nicola Fossati h, i, Tobias Gross j, Ann M. Henry k, Steven Joniau l, Thomas B. Lam m, n, Malcolm D. Mason o, Vsevolod B. Matveev p, Paul C. Moldovan q, Roderick C.N. van den Bergh r, Thomas Van den Broeck s, Henk G. van der Poel t, Theo H. van der Kwast f, Olivier Rouvière q, Ivo G. Schoots u, Thomas Wiegel v, Philip Cornford w

a Department of Urology, University Hospital, St. Etienne, France; b Bladder Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA; c Department of Radiation Therapy, CHU Grenoble, Grenoble, France; d Patient Advocate, Hasselt, Belgium; e Academic Urology Unit, University of Sheffield, Sheffield, UK; f University of Warwick, Cancer Research Centre, Coventry, UK; g Unit of Urology/Division of Oncology, UR1, IRCCS Ospedale San Raffaele, Milan, Italy; h Università Vita-Salute San Raffaele, Milan, Italy; i Department of Urology, University of Bern, Inselspital, Bern, Switzerland; j Leeds Cancer Centre, St. James's University Hospital, Leeds, UK; k University of Leeds, Leeds, UK; l Department of Urology, University Hospitals Leuven, Leuven, Belgium; m Academic Urology Unit, University of Aberdeen, Aberdeen, UK; n Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK; o Cardiff University, Velindre Hospital, Cardiff, UK; p N.N. Blokhin Cancer Research Center, Moscow, Russia; q Hospices Civils de Lyon, Radiology Department, Edouard Herriot Hospital, Lyon, France; r Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands; s Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands; t Department of Pathology, Erasmus Medical Centre, Rotterdam, The Netherlands; u Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Centre, Rotterdam, The Netherlands; v Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany; w Royal Liverpool and Broadgreen Hospitals NHS Trust, Liverpool, UK

Objective: To present a summary of the 2016 version of the European Association of Urology (EAU) – European Society for Radiotherapy & Oncology (ESTRO) – International Society of Geriatric Oncology (SIOG) Guidelines on screening, diagnosis, and local treatment with curative intent of clinically localised prostate cancer (PCa).

Evidence acquisition: The working panel performed a literature review of the new data (2013–2015). The guidelines were updated and the levels of evidence and/or grades of recommendation were added based on a systematic review of the evidence.

Evidence synthesis: BRCA2 mutations have been added as risk factors for early and aggressive disease. In addition to the Gleason score, the five-tier 2014 International Society of Urological Pathology grading system should now be provided. Systematic screening is still recommended. Instead, an individual risk-adapted strategy following a detailed discussion and taking into account the patient’s wishes and life expectancy must be considered. An early prostate-specific antigen test, the use of a risk calculator, or one of the promising biomarker tools are being investigated and might be able to limit the overdetection of insignificant PCa. Breaking the link between diagnosis and treatment may lower the overtreatment risk. Multiparametric magnetic resonance imaging using standardised reporting cannot replace systematic biopsy, but robustly nested within the diagnostic work-up, it has a key role in local staging. Active surveillance always needs to be discussed with very low-risk patients. The place of surgery in high-risk disease and the role of lymph node dissection have been clarified, as well as the management of node-positive patients. Radiation therapy using dose-escalated inten-
1. Introduction

The most recent summary of the European Association of Urology (EAU) Guidelines on prostate cancer (PCa) was published in 2013 [1]. This update is based on structured yearly literature reviews and systematic review through an ongoing process. Evidence levels and grade of recommendation have been inserted according to the general principles of evidence-based medicine [2].

PCa remains the most common cancer in men in Europe (excluding skin cancer). Although the incidence of autopsy-detected cancers is roughly the same in different parts of the world, the incidence of clinically diagnosed PCa varies widely and is highest in Northern and Western Europe (>200 per 100 000 men/year) [3]. This is suggested to be a consequence of exogenous factors such as diet, chronic inflammation, sexual behaviour, and low exposure to ultraviolet radiation [4].

Metabolic syndrome has been linked with an increased risk of PCa [5], but there is insufficient evidence to recommend lifestyle changes or a modified diet to lower this risk. In hypogonadal men, testosterone therapy is not associated with an increased PCa risk [6]. No drugs or food supplements have been approved for PCa prevention.

Apart from age and African American origin, a family history of PCa (both paternal and maternal [7]) are well-established risk factors. If one first-degree relative has PCa, the risk is at least doubled. It increases by 5–11 times when two or more first-line relatives are affected [8]. About 9% of men with PCa have truly hereditary disease, which is associated with an onset 6–7 yr earlier than spontaneous cases, but does not differ in other ways. The only exception to this are carriers of the rare BRCA2 germline abnormality, who seem to have an increased risk of early-onset PCa with aggressive behaviour [9–11].

2. Classification

The 2009 TNM classification for staging of PCa and the EAU risk group classification are used (Table 1). The latter classification is based on grouping patients with a similar risk of biochemical recurrence after local treatment.

The International Society of Urological Pathology (ISUP) 2005 modified Gleason score (GS) is the recommended PCa grading system. The biopsy GS consists of the Gleason grade of the most extensive pattern plus the highest pattern, regardless its extent. In radical prostatectomy (RP) specimens, the GS is determined differently: A pattern comprising ≤5% of the cancer volume is not incorporated in the GS, but its proportion should be reported separately if it is grade 4 or 5.

<table>
<thead>
<tr>
<th>Low-risk</th>
<th>Intermediate-risk</th>
<th>High-risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSA &lt; 10 ng/mL, and GS &lt; 7</td>
<td>PSA 10–20 ng/mL, or GS 7</td>
<td>PSA &gt; 20 ng/mL, or GS &gt; 7</td>
</tr>
<tr>
<td>and cT1-2a</td>
<td>or cT2b</td>
<td>or cT2c</td>
</tr>
<tr>
<td>Localised</td>
<td>Localised</td>
<td>Localised</td>
</tr>
</tbody>
</table>

GS = Gleason score; PSA = prostate-specific antigen.
The 2014 ISUP Gleason Grading Conference on Gleason Grading of Prostate Cancer [12] adopted the concept of grade groups of PCa to align PCa grading with the grading of other carcinomas, eliminate the anomaly that the most highly differentiated PCas have a GS 6 and highlight the clinical differences between GS 7 (3 + 4) and 7 (4 + 3) (Table 2).

### 3. Screening and early detection

Screening for PCa remains one of the most controversial topics in the urologic literature. A Cochrane review [13] suggests that PSA screening is associated with an increased diagnosis rate (relative risk [RR]: 1.3; 95% confidence interval [CI], 1.02–1.65), the detection of more localised (RR: 1.79; 95% CI, 1.19–2.70) and less advanced disease (T3–4, N1, M1) (RR: 0.80; 95% CI, 0.73–0.87). However, neither overall survival (OS: RR: 1.00; 95% CI, 0.96–1.03) nor cancer-specific survival (CSS) benefit were observed (RR: 1.00; 95% CI, 0.86–1.17). Moreover, screening was associated with overdiagnosis and overtreatment. All these considerations have led to a strong advice against systematic population-based screening in Europe and the United States. And yet the population-based European Randomised Study of Screening for Prostate Cancer (ERSPC) showed a reduction in PCa mortality in the screening arm (RR: 0.8; 95% CI, 0.65–0.98) after a median follow-up of 9 yr. Updated results from the ERSPC at 13 yr of follow-up showed an unchanged cancer-specific mortality reduction [14], but the number needed to screen and to treat to avoid one death from PCa decreased and is now below the number needed to screen in breast cancer trials [15] (Table 3). But an OS benefit is still lacking. The uptake of the current US Preventive Services Task Force recommendations has been associated with a substantial number of men with aggressive disease being missed [16]. Finally, a comparison of systematic and opportunistic screening suggested overdiagnosis and mortality reduction by systematic screening versus a higher opportunistic screening suggested overdiagnosis and overtreatment. All these factors have led to a strong advice against systematic population-based screening in Europe and the United States. And yet the population-based European Randomised Study of Screening for Prostate Cancer (ERSPC) showed a reduction in PCa mortality in the screening arm (RR: 0.8; 95% CI, 0.65–0.98) after a median follow-up of 9 yr. Updated results from the ERSPC at 13 yr of follow-up showed an unchanged cancer-specific mortality reduction [14], but the number needed to screen and to treat to avoid one death from PCa decreased and is now below the number needed to screen in breast cancer trials [15] (Table 3). But an OS benefit is still lacking. The uptake of the current US Preventive Services Task Force recommendations has been associated with a substantial number of men with aggressive disease being missed [16]. Finally, a comparison of systematic and opportunistic screening suggested overdiagnosis and mortality reduction by systematic screening versus a higher opportunistic screening with at best a marginal survival benefit after opportunistic screening [17].

Targeting men at higher risk of PCa might reduce the number of unnecessary biopsies. These include men aged >50 yr (>45 yr in African American men) or with a family history of PCa. In addition men with a PSA >1 ng/ml at age 40 yr and >2 ng/ml at age 60 yr [18,19] are at increased risk of PCa metastasis or death several decades later. Risk calculators developed from cohort studies may also be useful in reducing the number of unnecessary biopsies. None has clearly shown superiority over each other or can be considered as optimal [20].

Optimal intervals for PSA testing and digital rectal examination (DRE) follow-up are unknown. A 2-yr interval for men at increased risk, while it could be expanded up to 8 yr for those not at risk. The age at which to stop early diagnosis should be based on individual’s life expectancy, where comorbidity is at least as important as age [21]. Men who have <15 yr of life expectancy are unlikely to benefit.

All the available tools will still lead to some overdiagnosis. Breaking the link between diagnosis and active treatment is the only way to decrease the risk of overtreatment while maintaining the potential benefit of individual early diagnosis for men requesting it (Table 4).

### 4. Diagnosis

PCa is usually suspected on the basis of DRE and/or an elevated PSA. Definitive diagnosis depends on histopathologic verification. Abnormal DRE is an indication for biopsy, but as an independent variable, PSA is a better predictor of cancer than either DRE or transrectal ultrasound (TRUS).
PSA is a continuous parameter, with higher levels indicating greater likelihood of PCa, precluding an optimal PSA threshold for detecting nonpalpable but clinically significant PCa. A limited PSA elevation alone should be confirmed after a few weeks under standardised conditions (i.e., no ejaculation, manipulations, and urinary tract infections) in the same laboratory before considering a biopsy. The empiric use of antibiotics in an asymptomatic patient should not be undertaken [22].

The free-to-total PSA ratio stratifies the risk of PCa in men with 4–10 ng/ml total PSA and a previous negative biopsy but may be affected by several preanalytical and clinical factors (e.g., instability of free PSA at 4 °C and room temperature, variable assay characteristics, and large concomitant benign prostatic hyperplasia [BPH]). Novel assays for risk stratification measuring a panel of kallikreins including the Prostate Health Index test and the four-kallikrein score test are intended to reduce the number of unnecessary biopsies in men with a PSA between 2 and 10 ng/ml. Prospective multicentre studies demonstrated that both tests outperformed free-to-total PSA for PCa detection [23,24]. A formal comparison of these new tests is lacking.

5. **Prostate biopsy**

TRUS-guided biopsy using an 18G biopsy needle and a periprostatic block is the standard of care. When the same number of cores are taken, both transrectal and transperineal approaches have comparable detection rates [25,26].

Ten- to 12-core biopsies should be taken, bilateral from apex to base, as far posterior and lateral as possible from the peripheral gland. Additional cores should be obtained from DRE/TRUS suspect areas. Oral or intravenous quinolones are state-of-the-art preventive antibiotics, in spite of the increased resistance to quinolones, which is associated with a rise in severe infectious complications [27]. Other biopsy complications include haematospermia (37%), haematuria lasting >1 d (14.5%), and rectal bleeding lasting ≤2 d (2.2%). Each biopsy site should be reported individually, including its location, the ISUP 2005 GS, and extent. ISUP 2014 grade should be given as a global grade, taking into account the Gleason grades of cancer foci in all biopsy sites. If identified, intraductal carcinoma, lymphovascular invasion, perineural invasion, and extraprostatic extension must each be reported. Table 5 summarises the indications for repeat biopsy following an initial negative biopsy.

Many single-centre studies suggest that multiparametric magnetic resonance imaging (mpMRI) can reliably detect aggressive tumours with a negative predictive value (NPV) and positive predictive value ranging from 63% to 98% and from 34% to 68%, respectively [28]. The combination of systematic and targeted biopsies (MRI-Tbx) may also better predict the final GS [29]. As a result, some authors proposed performing systematic mpMRI before a prostate biopsy [30,31]. One meta-analysis suggested that MRI-Tbx had a higher detection rate of clinically significant PCa compared with TRUS biopsy (sensitivity 0.91 vs 0.76) and a lower rate of detection of insignificant PCa (sensitivity 0.44 vs 0.83). However, this benefit was restricted to the repeated biopsy subgroup [32]. Two more recent randomised controlled trials (RCTs) restricted to the initial biopsy yielded contradictory results regarding the added value of MRI-Tbx combined with systematic biopsies [33,34]. Major limitations of mpMRI are its interobserver variability and the heterogeneity in the definitions of positive and negative examinations. The first version of the Prostate Imaging Reporting and Data System (PI-RADS) scoring system failed to improve interobserver variability as compared with subjective scoring [35]. An updated version (PI-RADS v2) needs to be evaluated further [36].

6. **Staging of prostate cancer**

The decision to proceed with a further staging work-up is guided by which treatment options are available, taking into account the patient’s preference and comorbidity. A summary of the guidelines is presented in Table 6.

---

**Table 5 – Indications for rebiopsy after a negative biopsy and the associated risk to find a prostate cancer**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Associated PCa risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rising and/or persistently elevated PSA</td>
<td>–</td>
</tr>
<tr>
<td>Suspicious DRE</td>
<td>5–30%</td>
</tr>
<tr>
<td>Atypical small acinar proliferation (i.e., atypical glands suspicious for cancer)</td>
<td>40%</td>
</tr>
<tr>
<td>Extensive (ie, &gt;3 biopsy sites) high-grade PIN</td>
<td>&lt;30%</td>
</tr>
<tr>
<td>Few atypical glands immediately adjacent to high-grade PIN</td>
<td>50%</td>
</tr>
<tr>
<td>Intraductal carcinoma as a solitary finding</td>
<td>&gt;90% (mainly high-grade PCa)</td>
</tr>
<tr>
<td>Positive mpMRI</td>
<td>34–68%</td>
</tr>
</tbody>
</table>

DRE = digital rectal examination; mpMRI = multiparametric magnetic resonance imaging; PCa = prostate cancer; PIN = prostatic intraepithelial neoplasia; PSA = prostate-specific antigen.

**Table 6 – Guidelines for staging of prostate cancer**

<table>
<thead>
<tr>
<th>Risk group</th>
<th>LE</th>
<th>GR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Any risk group staging</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Do not use CT and TRUS for local staging</td>
<td>2a</td>
<td>A</td>
</tr>
<tr>
<td><strong>Low-risk localised PCa</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Do not use additional imaging for staging purposes</td>
<td>2a</td>
<td>A</td>
</tr>
<tr>
<td><strong>Intermediate-risk PCa</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In predominantly Gleason pattern 4, metastatic screening, include at least cross-sectional abdominopelvic imaging (s.a. CT/MRI) and a bone scan for staging purposes</td>
<td>2a</td>
<td>A*</td>
</tr>
<tr>
<td>In predominantly Gleason pattern 4, use prostate mpMRI for local staging</td>
<td>2b</td>
<td>A</td>
</tr>
<tr>
<td><strong>High-risk localised PCa or high-risk locally advanced PCa</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use prostate mpMRI for local staging</td>
<td>2b</td>
<td>A</td>
</tr>
<tr>
<td>Perform metastatic screening including at least cross-sectional abdominopelvic imaging and a bone-scan</td>
<td>2a</td>
<td>A</td>
</tr>
</tbody>
</table>

CT = computed tomography; GR = grade of recommendation; LE = level of evidence; mpMRI = multiparametric magnetic resonance imaging; MRI = magnetic resonance imaging; PCa = prostate cancer; TRUS = transrectal ultrasound.
7. **Primary local treatment**

Management decisions should be made after all options have been discussed with a multidisciplinary team (including urologists, radiation oncologists, medical oncologists, pathologists, and radiologists), and after the balance of benefits and side effects of each therapy modality has been considered together with the patient.

8. **Active surveillance and watchful waiting**

Active surveillance (AS) aims to reduce overtreatment in men with very low-risk PCa, without compromising opportunities for cure, whereas watchful waiting (WW) is a possible management for frail patients until the possible development of clinical progression leading to symptomatic treatment. The major differences between these two modalities are detailed in Table 7.

Mortality from untreated screen-detected PCa in patients with GS 5–7 can be as low as 7% at 15 yr follow-up [37]. An RCT was unable to show an OS and CSS difference at 10 yr between RP and WW in 731 men with screen-detected clinically organ-confined PCa [38]. Only patients with intermediate risk or with a PSA >10 ng/ml had a significant OS benefit from RP (hazard ratio [HR]: 0.69 [0.49–0.98] and 0.67 [0.48–0.94], respectively). A population-based analysis in 19 639 patients aged ≥65 yr who were not given curative treatment found that in men having a Charlson Comorbidity Index score ≥2, tumour aggressiveness had little impact on OS at 10 yr [39]. These data highlight the potential role of WW in some patients with an individual life expectancy <10 yr.

A systematic review summarised the available data on AS [40]. There is considerable variation between studies regarding patient selection, follow-up policies, and when active treatment should be instigated. Selection criteria for AS include clinical T1c or T2a, PSA <10 ng/ml, and PSA density <0.15 ng/ml per ml (even if still controversial [41]), fewer than two to three positive cores with <50% cancer involvement of every positive core, GS 6. Extraprostatic extension or lymphovascular invasion should not be considered for AS [42]. Rebiopsy to exclude Gleason sampling error is considered important [41], and mpMRI has a major role based on its high NPV value for lesion upgrading and to exclude anterior prostate lesions [43]. Follow-up in AS is based on repeat biopsy [41], serial PSA measurements, and DRE, the optimal schedule remaining unclear. Strategies how to incorporate mpMRI within this follow-up are evolving but are not yet established. The decision to switch to an active treatment is based on a change in the inclusion criteria (T stage and biopsy results). The use of a PSA change (especially a PSA doubling time <3 yr) remains contentious based on its weak link with grade progression. Active treatment may also be triggered upon a patient’s request [44].

9. **Radical prostatectomy**

The goal of RP is eradication of PCa while preserving continence and, whenever possible, potency. It is the only treatment for localised PCa to show a benefit for OS and CSS, compared with WW. Patients should not be denied this procedure on the grounds of age alone [21] provided they have at least 10 yr of life expectancy and are aware that increasing age is linked to increased incontinence risk. Nerve-sparing RP can be performed safely in most men with localised PCa. High risk of extracapsular disease, such as any cT2c or cT3 or any GS >7, are usual contraindications. An externally validated nomogram predicting side-specific extracapsular extension can help guide decision making [45]. mpMRI may be helpful for selecting a nerve-sparing approach because it has good specificity (0.91; 95% CI, 0.88–0.93) but low sensitivity (0.57; 95% CI, 0.49–0.64) for detecting microscopic pT3a stages [46]. But the experience of the radiologist remains of paramount importance.

Lower rates of positive surgical margins for high-volume surgeons suggest that experience and careful attention to surgical details can improve surgical cancer control [47] and lower the complication rate.

There is still no evidence that one surgical approach is better than another (open, laparoscopic, or robotic), as highlighted in a formal systematic review. Robot-assisted prostatectomy is associated with lower perioperative morbidity and a reduced positive margins rate compared with laparoscopic prostatectomy, although there is considerable methodological uncertainty. No formal differences exist in cancer-related continence or erectile dysfunction outcomes [48].

9.1. **Pelvic lymph node dissection**

The individual risk of finding positive lymph nodes can be estimated using externally validated preoperative nomograms such as that described by Briganti [49]. A risk of nodal

<table>
<thead>
<tr>
<th>Table 7 – Definitions of active surveillance and watchful waiting</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Active surveillance</strong></td>
</tr>
<tr>
<td>Treatment intent</td>
</tr>
<tr>
<td>Follow-up</td>
</tr>
<tr>
<td>Assessment/Markers used</td>
</tr>
<tr>
<td>Life expectancy</td>
</tr>
<tr>
<td>Aim</td>
</tr>
<tr>
<td>Comments</td>
</tr>
</tbody>
</table>

DRE = digital rectal examination; PSA = prostate-specific antigen; mpMRI = multiparametric magnetic resonance imaging.
metastases >5% is an indication to perform an extended nodal dissection (ePLND). This includes removal of the nodes overlying the external iliac artery and vein, the nodes within the obturator fossa located cranially and caudally to the obturator nerve, the nodes medial and lateral to the internal iliac artery, and the nodes overlying the common iliac artery and vein up to the ureteral crossing. It is recommended that for each region the nodes should be sent separately for pathologic analysis. With this template, 75% of all anatomic landing sites are cleared, resulting in improved pathological staging compared with a limited pelvic lymph node dissection, but at the cost of three-fold higher complication rates (19.8% vs 8.2%), mainly related to significant lymphocelecs [50].

In men with pN+ PCa, early adjuvant androgen-deprivation therapy (ADT) was shown to achieve a 10-yr CSS rate of 80% [51]. Improving local control with pelvic radiation therapy (RT) combined with ADT appeared to be beneficial in pN1 PCa patients treated with an ePLND. Men with minimal-volume nodal disease (fewer than three lymph nodes) and GS 7–10 and pT3–4 or R1 as well as men with three to four positive nodes were more likely to benefit from combined ADT and RT after surgery [52].

9.2. Low-risk prostate cancer

The decision to offer RP should be based on the probabilities of clinical progression, side effects, and potential survival benefit. No lymph node dissection is needed.

9.3. Intermediate-risk localized prostate cancer

Data from SPCG-4 [53] and a preplanned subgroup analysis (PIVOT) [36] highlight the benefit of RP compared to WW. The risk of having positive nodes is 3.7–20.1% [49]. An ePLND should be performed if the estimated risk for pN+ exceeds 5% [49]. In all other cases, nodal dissection can be omitted while accepting a low risk of missing positive nodes.

9.4. High-risk and locally advanced prostate cancer

Patients with high-risk and locally advanced PCa are at an increased risk of PSA failure, need for secondary therapy, metastatic progression, and death from PCa. Provided that the tumour is not fixed and not invading the urethral sphincter, RP combined with an ePLND is a reasonable first step in a multimodal approach. The estimated risk for pN+ is 15–40% [49]. Regarding each individual high-risk factor in patients treated with a multimodal approach, a GS 8–10 prostate-confined lesion has a good prognosis after RP. In addition, frequent downgrading exists between the biopsy and the specimen GS [54]. At 10- and 15-yr follow-up, the CSS is up to 88% and 66%, respectively [55,56]. A PSA >20 ng/ml is associated with a CSS at 10 and 15 yr ranging between 83% and 91% and 71% and 85%, respectively [55–57]. Surgery has traditionally been discouraged for cT3N0 PCa, mainly because of the increased risk of positive margins and lymph node metastases and/or distant relapse. Retrospective case series demonstrated a CSS at 10 and 15 yr between 85% and 92% and 62% and 84%, respectively; 10-yr OS ranged between 76% and 77% [58]. The overall heterogeneity of this high-risk group was highlighted by a large retrospective multicentre cohort of 1360 high-risk patients treated with RP in a multimodal approach [58]. At 10 yr, a 91.3% CSS was observed. CSS was 95% for those having only one risk factor (ie, GS >7, cT category higher than cT2, or PSA >20 ng/ml), 88% for those having a cT3–4 and a PSA >20 ng/ml, and reduced to 79% if all three risk factors were present.

9.5. Side effects of radical prostatectomy

Postoperative incontinence and erectile dysfunction (ED) are common problems following RP. There is no major difference based on the surgical approach with an overall complication rate between 89% and 100% when a robotic procedure was conducted compared to 80–97% for the retropubic approach [59].

A prospective controlled nonrandomised trial of patients treated in 14 centres was published recently. At 12 mo after robotic surgery, 21.3% were incontinent, as were 20.2% after open. The adjusted OR was 1.08 (95% CI, 0.87–1.34). ED was observed in 70.4% after robotic and 74.7% after open. The adjusted OR was 0.81 (95% CI, 0.66–0.98) [60].

10. Definitive radiation therapy

Dose-escalated intensity-modulated radiation therapy (IMRT), with or without image-guided RT, is the gold standard for external-beam radiation therapy (EBRT) because it is associated with less toxicity compared to three-dimensional conformal radiation therapy (3D-CRT) techniques [61]. However, whatever the technique and their degree of sophistication, quality assurance plays a major role in the planning and delivery of RT.

RCTs have shown that escalating the dose into the range 74–80 Gy leads to a significant improvement in 5-yr biochemical-free survival [62–65]. In men with intermediate- or high-risk PCa, there is also evidence to support an OS benefit from a nonrandomised but well-conducted propensity matched retrospective analysis covering a total of 42,481 patients [66].

Biological modelling suggests that PCa may be sensitive to an increased dose per fraction resulting in the investigation in RCTs of hypofractionation (HFX) in localised disease. The largest reported randomised trial, using IMRT in predominantly intermediate-risk localised PCa, (CHHiP trial) demonstrates 60 Gy in 20 fractions (3 Gy/fraction) is non-inferior to 74 Gy in 37 fractions with 5-yr recurrence free rates of 90%. A third arm using 57 Gy in 19 fractions (3 Gy/fraction) was not demonstrated to be non-inferior in terms of biochemical control. No significant differences in the proportion or cumulative incidence of 5-yr toxicity were found when using the 3 Gy per fraction schedules [67]. Other trials have demonstrated increased toxicity with HFX. In the RTOG 0415 study, 70 Gy in 28 fractions (2.5 Gy/fraction) was investigated in low risk
PCa patients. Late Grade 2 GI and GU toxicities of 18.2% and 26.2% were noted with HFX compared to 11.4% and 20.5% using conventional fractionation [68]. Patient reported toxicity outcomes are awaited. Another randomised trial, using a higher dose per fraction of 3.4 Gy delivered to a total dose of 64.6 Gy (HYPRO trial), has demonstrated increased G3 and higher late urinary toxicity particularly in patients with pre-existing urinary symptoms [69]. HFX delivered with fewer treatments can increase the convenience for the patient and lower costs for the health care system, but only evidence based fractionation schedules should be used outside of clinical trials.

HFX requires meticulous quality assurance, excellent image guidance, and close attention to organ-at-risk dose constraints to minimise the long-term toxicity risk. Extreme HFX (5–10 Gy per fraction) in which radiation is delivered in five to seven fractions should still be considered as investigational.

10.1. Low-risk prostate cancer

Offer dose-escalated IMRT (74–78 Gy) without ADT.

10.2. Intermediate-risk prostate cancer

Patients suitable for ADT should be given combined dose-escalated IMRT (76–78 Gy) with short-term ADT (4–6 mo) [70]. For patients unsuitable for ADT (eg, due to comorbidities) or unwilling to accept ADT (eg, to preserve their sexual health), the recommended treatment is IMRT at a dose of 76–80 Gy or a combination of IMRT and brachytherapy.

10.3. Localised high-risk prostate cancer

The high risk of relapse outside the irradiated volume makes it mandatory to use a combined modality approach, consisting of dose-escalated IMRT, possibly including the pelvic lymphatics and long-term ADT, generally for 2 to 3 yr. The duration of ADT has to take into account performance status, comorbidities, and the number of poor prognostic factors.

10.4. Locally advanced prostate cancer: T3–4 N0, M0

The standard of care for patients T3–4 N0, M0 locally advanced PCa is IMRT combined with long-term ADT for at least 2 to 3 yr as it results in better OS [71–73]. The combination is clearly better than EBRT or ADT monotherapy [74]. In both high-risk localised and locally advanced PCa, an upfront combination with docetaxel only improves relapse-free survival, with no survival benefit at 9 yr [75].

10.5. Lymph node irradiation

In men with cN0 PCa, RCTs failed to show a benefit from prophylactic pelvic nodal irradiation (46–50 Gy) in high-risk cases [76]. In men with cN1 or pN1 the outcome of RT alone is poor, and these patients should receive RT plus long-term ADT, as shown by the STAMPEDE trial, in which the use of RT improved failure-free survival in men with N+ PCa [77].

10.6. Postoperative external-beam radiation therapy after radical prostatectomy

Extracapsular invasion and positive surgical margins are associated with a risk of local recurrence and progression. Adjuvant RT was associated with improved biochemical progression-free survival in three RCTs [78–80], although only SWOG 8794 [80] suggested improved OS. Thus for patients classified as pT3 pN0 with a high risk of local failure with positive margins (highest impact), pT3a and/or pT3b with a postoperative PSA <0.1 ng/ml, two options can be offered in the framework of informed consent. Either immediate EBRT to the surgical bed after recovery of urinary function or monitoring followed by early salvage RT before the PSA exceeds 0.5 ng/ml [81].

10.7. Side effects of definitive radiation therapy

The Memorial Sloan Kettering Cancer Center group reported data on late toxicity from their experience in 1571 patients with T1–T3 disease treated with either 3D-CRT or IMRT at doses between 66 Gy and 81 Gy, with a median follow-up of 10 yr [61]. The use of IMRT significantly reduced the risk of late grade 2 or higher gastrointestinal (GI) toxicity to 5% compared with 13% with 3D-CRT. The incidence of grade ≥2 late genitourinary (GU) toxicity was 20% in patients treated with 81 Gy IMRT versus 12% with lower doses. The overall incidences of late grade 3 toxicity were 1% and 3% for GI and GU toxicity, respectively.

Systematic review and meta-analysis of observational studies comparing patients exposed or unexposed to radiotherapy in the course of treatment for PCa demonstrate an increased risk of developing second cancers for bladder (OR: 1.39), colorectal (OR: 1.68), and rectum (OR: 1.62) with similar risks over lag times of 5 and 10 yr. Absolute risks over 10 yr are small (1–4%) but should be discussed with younger men in particular [82].

11. Brachytherapy

Low-dose rate (LDR) brachytherapy uses permanent radioactive seeds implanted into the prostate and is an option for those with low-risk disease and selected cases with intermediate-risk disease (low-volume GS 3 + 4), prostate volume <50 cm³, and an IPSS ≤12 [83]. Up to 85% relapse-free survival at 10 yr is demonstrated [84]. LDR as a boost with EBRT can be used to dose escalate radiation in intermediate- and high-risk patients. Although seen as a low-impact treatment modality, some patients experience significant urinary complications following implantation, such as urinary retention (1.5–22%), postimplantation transurethral resection of the prostate (TURP) (8.7% of cases), and incontinence (0–19%) [85]. Careful selection of patients using uroflowmetry can avoid these significant side effects [86]. Previous TURP for BPH increases the risk of
postimplantation incontinence and urinary morbidity. ED develops in about 40% of the patients after 3–5 yr. High-dose rate (HDR) brachytherapy uses a radioactive source temporarily introduced into the prostate to deliver radiation. HDR brachytherapy can be delivered in single or multiple fractions and is often combined with EBRT of at least 45 Gy as a method of dose escalation in intermediate- or high-risk PCa. Quality-of-life changes are similar to high-dose EBRT alone [87]. HDR brachytherapy as monotherapy has been pioneered in a small number of centres with low toxicity and high biochemical control rates but currently mature data are not available on the optimal treatment schedule [88].

12. **Alternative local treatment options**

Besides RP, EBRT, and brachytherapy, other modalities have emerged as therapeutic options in patients with clinically localised PCa. However patients with a life expectancy >10 yr should be fully informed that there are limited data on the long-term outcome for cancer control beyond 10 yr. Recently, focal therapy has been developed, with the aim to ablate tumours selectively while sparing the neurovascular bundles, sphincter, and urethra. Based on the available data [89], it should still be considered as fully experimental.

Cryosurgery might be considered for patients with an organ-confined PCa or minimal tumour extension beyond the prostate, prostate volumes <40 ml, PSA <20 ng/ml, and GS <7.

A systematic review compared cryotherapy versus RP and EBRT [89]. Data from 3995 patients across 19 studies were included. In the short term, there was conflicting evidence relating to cancer-specific outcomes. The 1-yr disease-free survival was worse for cryotherapy than for either EBRT or RP. None of the other cancer-specific outcomes including OS showed any significant differences. The high risk of bias across studies precludes any clear conclusions.

High-intensity focussed ultrasound (HIFU) of the prostate was compared in a systematic review [89] with RP and EBRT as primary treatment for localised PCa. Data from 4000 patients across 21 studies were included. HIFU had a significantly worse disease-free survival at 1 yr compared with EBRT. The biochemical result was in contrast to OS at 4 yr, which was higher when using HIFU. The quality of the evidence was poor, due to high risks of bias across studies precluding any clear conclusion. The overall PCa Guidelines are summarised in Table 8.

Table 8 – Summary of the main findings regarding treatment of nonmetastatic prostate cancer

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>LE</th>
<th>GR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management decisions should be made after all treatments have been discussed in a multidisciplinary team</td>
<td>4</td>
<td>A</td>
</tr>
<tr>
<td>Offer RP to patients with low- and intermediate-risk PCa and a life expectancy &gt;10 yr</td>
<td>1b</td>
<td>A</td>
</tr>
<tr>
<td>Nerve-sparing surgery may be attempted in preoperatively potent patients with low risk for extracapsular disease</td>
<td>2b</td>
<td>B</td>
</tr>
<tr>
<td>In intermediate- and high-risk disease, use mpMRI as a decision tool to select patients for nerve-sparing procedures</td>
<td>2b</td>
<td>B</td>
</tr>
<tr>
<td>Offer RP in a multimodality setting to patients with high-risk localised PCa and a life expectancy &gt;10 yr</td>
<td>2a</td>
<td>A</td>
</tr>
<tr>
<td>Offer RP in a multimodality setting to selected patients with locally advanced (cT3a) PCa and a life expectancy &gt;10 yr</td>
<td>2b</td>
<td>B</td>
</tr>
<tr>
<td>Offer RP in a multimodality setting to highly selected patients with locally advanced PCa (cT3b–4 N0 or any T N1)</td>
<td>3</td>
<td>C</td>
</tr>
<tr>
<td>Do not offer NHT before RP</td>
<td>1a</td>
<td>A</td>
</tr>
<tr>
<td>Do not offer adjuvant HT for pN0</td>
<td>1a</td>
<td>A</td>
</tr>
<tr>
<td>Offer adjuvant ADT for node positive (pN+)</td>
<td>1b</td>
<td>A</td>
</tr>
<tr>
<td>Offer EBRT using IMRT to all risk groups</td>
<td>2a</td>
<td>A</td>
</tr>
<tr>
<td>In patients with low-risk PCa, without a previous TURP, with a good IPSS and a prostate volume &lt;50 ml, offer LDR brachytherapy</td>
<td>2a</td>
<td>A</td>
</tr>
<tr>
<td>In low risk PCa, use a total dose of 74–78 Gy</td>
<td>1a</td>
<td>A</td>
</tr>
<tr>
<td>In intermediate-risk PCa use a total dose of 76–78 Gy, in combination with short-term ADT (4–6 mo)</td>
<td>1b</td>
<td>A</td>
</tr>
<tr>
<td>In patients with high-risk localised PCa, use a total dose of 76–78 Gy in combination with long-term ADT (2–3 yr)</td>
<td>1b</td>
<td>A</td>
</tr>
<tr>
<td>In patients with locally advanced cN0 PCa, offer radiation therapy in combination with long-term ADT (2–3 yr)</td>
<td>1a</td>
<td>A</td>
</tr>
<tr>
<td>In patients with cN1 PCa, offer pelvic external irradiation in combination with immediate long-term ADT</td>
<td>2b</td>
<td>B</td>
</tr>
<tr>
<td>Offer adjuvant ADT for pN1 after ePLND</td>
<td>1b</td>
<td>A</td>
</tr>
<tr>
<td>Discuss adjuvant ADT with additional radiation therapy for pN1 after ePLND</td>
<td>2b</td>
<td>A</td>
</tr>
<tr>
<td>Offer observation (expectant management) for pN1 after ePLND when two or fewer nodes show microscopic involvement with a PSA &lt;0.1 ng/ml and absence of extranodal extension</td>
<td>2b</td>
<td>B</td>
</tr>
<tr>
<td>In patients with pT3N0M0 PCa and an undetectable PSA following RP, discuss adjuvant EBRT because it at least improves biochemical-free survival</td>
<td>1a</td>
<td>A</td>
</tr>
<tr>
<td>Neoadjuvant hormone therapy</td>
<td>1a</td>
<td>A</td>
</tr>
<tr>
<td>Only offer cryotherapy and HIFU within a clinical trial</td>
<td>2b</td>
<td>A</td>
</tr>
<tr>
<td>Do not offer focal therapy of the prostate outside a clinical trial</td>
<td>3</td>
<td>B</td>
</tr>
<tr>
<td>ADT = androgen-deprivation therapy; EBRT = external beam radiation therapy; ePLND = extended pelvic lymph node dissection; GR = grade of recommendation; GS = Gleason score; HIFU = high-intensity focussed ultrasound; HT = hormone therapy; IMRT = intensity-modulated radiation therapy; IPSS = International Prostate Symptom Score; LDR = low-dose rate; LE = level of evidence; mpMRI = multiparametric magnetic resonance imaging; NHT = neoadjuvant hormone therapy; PCa = prostate cancer; PSA = prostate-specific antigen; RP = radical prostatectomy; TURP = transurethral resection of the prostate.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Upgraded following Panel consensus.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
13. Conclusions


Author contributions: Nicolas Mottet had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Mottet, Cornford.

Acquisition of data: Mottet, Bolla, De Santis, Henry, Joniau, Lam, Mason, Matveev, Moldovan, van den Bergh, Van den Broeck, van der Poel, van der Kwast, Rouvière, Wiegel, Cornford.

Analysis and interpretation of data: Mottet, Bolla, Briers, De Santis, Henry, Joniau, Lam, Mason, Matveev, Moldovan, van den Bergh, van der Poel, van der Kwast, Rouvière, Wiegel, Cornford.

Drafting of the manuscript: Mottet.

Critical revision of the manuscript for important intellectual content: Mottet, Bellmunt, Bolla, Briers, Cumberbatch, De Santis, Fossati, Gross, Henry, Joniau, Lam, Mason, Matveev, Moldovan, van den Bergh, Van den Broeck, van der Poel, van der Kwast, Rouvière, Schoots, Wiegel, Cornford.

Statistical analysis: None.

Obtaining funding: None.

Administrative, technical, or material support: None.

Supervision: Mottet.

Other (specify): None.

Financial disclosures: Nicolas Mottet certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Nicolas Mottet receives speakers honoraria and consultation fees from Takeda Pharmaceutical, Millennium, Astellas, Pfizer, Novartis, Sanofi, and Pasteur. He receives honoraria or consultation fees from Takeda Pharmaceutical, Millennium, Janssen, Astellas, BMS, Bayer, Ipsen, Ferring, Novartis, Nucletron, Pierre Fabre, Sanofi, and Zeneca. Joaquim Bellmunt is a company consultant for Janssen, Astellas, Pierre Fabre, Genentech, Merck, Ipsen, Pfizer, Novartis and Sanofi Aventis. He has received research support from Takeda, Novartis and Sanofi and received travel grants from Pfizer and Pierre Fabre. Michel Bolla receives company honoraria from Ipsen and Astra Zeneca, is a company consultant for Janssen, and receives travel grants from Janssen, AstraZeneca, and Astellas. Erik Briers is a liaison officer for the European Prostate Cancer Coalition, a member of the ethics committee/patient advisory group for REQUITE (Validating predictive models and biomarkers of radiotherapy toxicity to reduce side effects and improve quality of life in cancer survivors), member of ESR-PAG (patient advisory group on medical imaging), member of the Skeletal Care Academy, and member of the European Medicines Agency’s Patients’ and Consumers’ Working Party. Maria De Santis is a company consultant for Glaxo Smith Kline, Janssen, Bayer, Novartis, Pierre Fabre, Astellas, Amgen, Eisai Inc., ESSA, Merck, and Synthor. She receives company speaker honoraria from Pfizer, Takeda, Sanofi Aventis, Shionogi, Celgene, and Teva Oncogenex, participates in trials for Pierre Fabre, Astellas, and Roche, and receives fellowships and travel grants from Bayer, Novartis, Ferring, Astellas, Sanofi Aventis, and Janssen. She receives grants/research support from Pierre Fabre and honoraria from AstraZeneca, participates in trials for Exelixis, Bayer, and Roche, and is a company consultant for Synthor. Steven Joniau is a company consultant for Astellas, Ipsen, Bayer, Sanofi, and Janssen. He receives company honoraria from Astellas, Amgen, Bayer, Sanofi, Janssen, and Ipsen, participates in trials for Astellas, Bayer, and Janssen, receives fellowships and travel grants from Astellas, Amgen, Bayer, Sanofi, Janssen, Ipsen, and Pfizer. Thomas B. Lam is a company consultant for Pfizer, GSK, Astellas, and Ipsen, receives company speaker honoraria from Pfizer, GSK, Astellas, and Ipsen. Malcolm D. Mason is a company consultant for Bristol-Myers Squibb, Janssen, Bayer, Sanofi, and Dendreon, and he receives company speaker honoraria from Takeda and Bayer. Seva Matveev participates in trials for Astellas, Pfizer, and Novartis, and he receives company speaker honoraria from Sanofi and Astellas. Henk G. van der Poel is a company consultant for Intuitive Surgical and participates in trials for Astellas and Steba Biotech. He receives grants/research support from Astellas. Olivier Rouvière is a company consultant for EDAP-TMS, Bracco, and Philips. He receives company speaker honoraria from EDAP-TMS and Bracco and participates in trials in EDAP-TMS and Bracco. Thomas Wiegel receives company speaker honoraria from Astellas, Takeda, Hexal, Ipsen, Janssen-Cilac, and Ferring. Philip Cornford is a company consultant for Astellas, Ipsen and Ferring. He receives company speaker honoraria from Astellas, Janssen, Ipsen and Pfizer and participates in trials from Ferring, and receives fellowships and travel grants from Astellas and Janssen. Marcus G. Cumberbatch, Nicola Fossati, Tobias Gross, Ann M. Henry, Paul L. Moldovan, Ivo G. Schoots, Roderick C.N. van den Bergh, Thomas Van den Broeck, and Theo van der Kwast have nothing to disclose.

Funding/Support and role of the sponsor: None.

References


[80] Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk


